Literature DB >> 11422616

Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection.

C Y Dai1, M L Yu, W L Chuang, Z Y Lin, S C Chen, M Y Hsieh, L Y Wang, J F Tsai, W Y Chang.   

Abstract

BACKGROUND: Hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common causes of chronic liver disease, cirrhosis and hepatocellular carcinoma. The influence of HCV infection on the clinicopathological and virological profiles of chronic HBV infection was investigated.
METHODS: A total of 100 chronic HBV carriers with histopathological diagnoses by liver biopsy were studied. Hepatitis B e antigen (HBeAg) and anti-HCV antibody were tested. Serum HCV-RNA was detected by using a nested reverse transcription-PCR assay. A branched DNA (bDNA) assay was used to detect HBV-DNA and quantitate the serum levels.
RESULTS: Eighteen (18%) of 100 patients were positive for anti-HCV and HCV-RNA. Patients with concurrent HCV and HBV infection were significantly older than those without HCV infection (P < 0.05). The positive rates of HBeAg and HBV-DNA as well as the serum levels of HBV-DNA in patients with concurrent HCV and HBV infection were significantly lower than those without concurrent HCV and HBV infection (P < 0.01, P < 0.05, and P < 0.001, respectively). By using multivariate analysis, the factors of seroconversion of HBeAg and decreasing level of HBV-DNA were significantly correlated to concurrent HCV and HBV infection in chronic HBV carriers. The factors of increasing age and concurrent HCV and HBV infection were significantly correlated to seroconversion of HBeAg.
CONCLUSIONS: The concurrent HCV and HBV infection in chronic HBV carriers might result in a suppression of HBV replication that presented with a lower level of serum HBV-DNA and HBeAg seroconversion. Nevertheless, neither more obvious increase in biochemical parameters nor histopathological progression to more advanced liver diseases was observed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11422616     DOI: 10.1046/j.1440-1746.2001.02494.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  14 in total

Review 1.  Management of chronic hepatitis B in patients from special populations.

Authors:  Ching-Lung Lai; Man-Fung Yuen
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-01       Impact factor: 6.915

Review 2.  Significance and Management of Isolated Hepatitis B Core Antibody (Anti-HBc) in HIV and HCV: Strategies in the DAA Era.

Authors:  Jennifer J Chang; Neaka Mohtashemi; Debika Bhattacharya
Journal:  Curr HIV/AIDS Rep       Date:  2018-04       Impact factor: 5.071

Review 3.  Hepatitis B virus and hepatitis C virus dual infection.

Authors:  Gaia Caccamo; Francesca Saffioti; Giovanni Raimondo
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

4.  Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients.

Authors:  Gia L Tyson; Jennifer R Kramer; Zhigang Duan; Jessica A Davila; Peter A Richardson; Hashem B El-Serag
Journal:  Hepatology       Date:  2013-07-01       Impact factor: 17.425

Review 5.  Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection.

Authors:  Seth D Crockett; Emmet B Keeffe
Journal:  Ann Clin Microbiol Antimicrob       Date:  2005-09-13       Impact factor: 3.944

Review 6.  The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management.

Authors:  Dimitris Konstantinou; Melanie Deutsch
Journal:  Ann Gastroenterol       Date:  2015 Apr-Jun

7.  The Hepatitis Viral Status in Patients With Hepatocellular Carcinoma: a Study of 3843 Patients From Taiwan Liver Cancer Network.

Authors:  Il-Chi Chang; Shiu-Feng Huang; Pei-Jer Chen; Chi-Ling Chen; Chao-Long Chen; Cheng-Chung Wu; Cheng-Chung Tsai; Po-Huang Lee; Miin-Fu Chen; Chuan-Mo Lee; Hsien-Chung Yu; Gin-Ho Lo; Chau-Ting Yeh; Chih-Chen Hong; Hock-Liew Eng; John Wang; Hui-Hwa Tseng; Cheng-Hsiang Hsiao; Hong-Dar Isaac Wu; Tseng-Chang Yen; Yun-Fan Liaw
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

8.  Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C.

Authors:  Ioanna Aggeletopoulou; Christos Konstantakis; Spilios Manolakopoulos; Christos Triantos
Journal:  World J Gastroenterol       Date:  2017-06-28       Impact factor: 5.742

9.  Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C.

Authors:  Ming-Lun Yeh; Ching-I Huang; Chung-Feng Huang; Meng-Hsuan Hsieh; Ming-Yen Hsieh; Zu-Yau Lin; Shinn-Cherng Chen; Jee-Fu Huang; Po-Lin Kuo; Hsing-Tao Kuo; Chia-Yen Dai; Ming-Lung Yu; Wan-Long Chuang
Journal:  Oncotarget       Date:  2018-01-13

10.  Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study.

Authors:  Ming-Lun Yeh; Ming-Yen Hsieh; Ching-I Huang; Chung-Feng Huang; Meng-Hsuan Hsieh; Po-Cheng Liang; Yi-Hung Lin; Nai-Jen Hou; Zu-Yau Lin; Shinn-Cherng Chen; Jee-Fu Huang; Chia-Yen Dai; Wan-Long Chuang; Ming-Lung Yu
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.